{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-004197","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.628185+00:00","generated_at":"2026-05-27T01:18:52.139891+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sangamo reports updated Phase 1/2 STAAR data for ST-920; eGFR slope +3.061; FDA Accelerated Approval path confirmed","bullets":["33 patients treated; gene therapy ST-920 generally well-tolerated; no deaths or discontinuations.","ERT-naïve/pseudo-naïve patients showed sustained α-Gal A activity up to 42 months; 17/18 ERT patients remain off ERT.","23 patients with ≥12 months follow-up: mean annualized eGFR slope +3.061 (95% CI 0.863-5.258), indicating potential kidney improvement.","FDA agreed to Accelerated Approval using 52-week eGFR slope; BLA submission expected H2 2025.","Significant QoL (SF-36 General Health +10.6, p=0.0020) and GI symptom improvements; anti-α-Gal A antibodies reduced/eliminated in 9/10 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-004197","json":"https://secwatch.observer/filing/0001628280-25-004197.json","markdown":"https://secwatch.observer/filing/0001628280-25-004197.md","text":"https://secwatch.observer/filing/0001628280-25-004197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828025004197/0001628280-25-004197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828025004197/sgmo-20250206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:18:52.139891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}